Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin

• Published in: Hepatology (Baltimore, Md.) Vol. 38; no. 1; pp. 66 - 74
• Main Authors: Hoofnagle, Jay H., Ghany, Marc G., Kleiner, David E., Doo, Edward, Heller, Theo, Promrat, Kittichai, Ong, Janus, Khokhar, Farooq, Soza, Alejandro, Herion, David, Park, Yoon, Everhart, James E., Liang, T.Jake
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA Elsevier Inc 01.07.2003; W.B. Saunders; Wiley
• Subjects: Antiviral Agents - administration & dosage; Antiviral Agents - adverse effects; Biological and medical sciences; Biopsy; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus - drug effects; Hepacivirus - genetics; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - pathology; Human viral diseases; Humans; Infectious diseases; Interferon-alpha - administration & dosage; Interferon-alpha - adverse effects; Liver - pathology; Male; Medical sciences; Middle Aged; Ribavirin - administration & dosage; Ribavirin - adverse effects; RNA, Viral - analysis; Viral diseases; Viral hepatitis; Human; Drug combination; Alpha interferon; Hepatic disease; Ribavirin; Infection; Chemotherapy; Chronic; Viral disease; Maintenance treatment; Digestive diseases; Nucleosidic analog; Viral hepatitis C
• ISSN: 0270-9139; 1527-3350
• DOI: 10.1053/jhep.2003.50258

To assess the efficacy and safety of maintenance therapy with ribavirin alone in chronic hepatitis C, 108 patients were treated with the combination of interferon alfa and ribavirin for 24 weeks; those who failed to have a virologic response were offered enrollment in a randomized, double-blind, controlled trial of ribavirin (1,000-1,200 mg daily) versus placebo for the subsequent 48 weeks. Patients were monitored at regular intervals with symptom questionnaires, serum aminotransferase levels, hepatitis C virus (HCV) RNA levels, and complete blood counts and underwent liver biopsy at the completion of therapy. Among 108 patients, 50 were still HCV RNA positive after 24 weeks of treatment, of whom 34 agreed to be randomized to continue either ribavirin monotherapy or placebo. Among 17 patients who received placebo, there was no overall improvement in symptoms, serum alanine aminotransferase (ALT) levels, HCV RNA levels, or hepatic histology. Among the 17 patients who received ribavirin, serum ALT levels and necroinflammatory features of liver histology were improved, whereas symptoms, HCV RNA levels, and hepatic fibrosis scores were not changed significantly from baseline. Responses to ribavirin seemed to be categorical, such that 8 patients (47%) had definite improvement in liver histology. Patients with improved histology had improvements in serum ALT levels both on combination therapy and after switching to ribavirin monotherapy. In conclusion, continuation of ribavirin monotherapy may maintain serum biochemical improvements that occur during interferon-ribavirin combination therapy in some patients and that these improvements are often associated with decreases in necroinflammatory changes in the liver. Whether these improvements will ultimately result in prevention of progression of hepatitis C requires further study. (H epatology 2003;38:66-74.)